Risk for intracranial hemorrhage low with rivaroxaban

During 2 years, 172 of the 14,264 participants in the ROCKET AF trial experienced an intracranial hemorrhage, at a rate of about 0.68% per year, according to a subanalysis of the trial.

The ROCKET AF steering committee and researchers investigated predictors associated with intracranial hemorrhage in patients with nonvalvular atrial fibrillation who were randomly assigned to rivaroxaban (Xarelto, Janssen) or warfarin in the large, randomized ROCKET AF trial. None of the study participants had experienced intracranial hemorrhage at enrollment, but 53% suffered a prior stroke. During follow-up, intracerebral hemorrhage (n=128) was the most common intracranial hemorrhage event; subarachnoid hemorrhage, subdural hemorrhage and extradural hemorrhage also occurred.

Full story